Gelfo et al. [69] highlighted the collective contributions of the inflammatory cytokine CXCL8 to the reduced sensitivity to EGFR blockade and suggested that inhibition of CXCL8 in combination with cetuximab may yield an effective treatment strategy for CRC patients refractory to anti-EGFR targeting. This evidence concerns the gene CXCL8 and colorectal carcinoma.